Related references
Note: Only part of the references are listed.THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW
Mazen Al Mushref et al.
ENDOCRINE PRACTICE (2020)
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study
E. M. Presotto et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations
Anupam Kotwal et al.
THYROID (2020)
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee-Shing Chang et al.
ENDOCRINE REVIEWS (2019)
New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?
Arantzazu Barquin-Garcia et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)
A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer.
Cristiane Jeyce Gomes-Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients
Pauline Campredon et al.
PRESSE MEDICALE (2019)
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Gilda Varricchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma
Eva Kassi et al.
CANCER MEDICINE (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes
Inmaculada Peiro et al.
ENDOCRINE (2019)
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
Emma S. Scott et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution
F. Guaraldi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Thyroid dysfunctions secondary to cancer immunotherapy
P. Chalan et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Practical Recommendations for Diagnosis and Clinical Management
Romualdo Barroso-Sousa et al.
CANCER (2018)
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Pedro Iglesias
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment
Nisha Subhash Patel et al.
ONCOLOGIST (2018)
Expert opinion on thyroid complications in immunotherapy
Frederic Illouz et al.
ANNALES D ENDOCRINOLOGIE (2018)
MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR TOXICITIES: A REVIEW AND CLINICAL GUIDELINE FOR EMERGENCY PHYSICIANS
Adam T. Hryniewicki et al.
JOURNAL OF EMERGENCY MEDICINE (2018)
Thyroid disorders induced by checkpoint inhibitors
Silvia Martina Ferrari et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2018)
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
Monica Girotra et al.
JNCI CANCER SPECTRUM (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Vincent Sibaud et al.
CURRENT OPINION IN ONCOLOGY (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Immune Modulation in Cancer with Antibodies
David B. Page et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Mario E. Lacouture et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy
Yulia Bronstein et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2011)
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Amod A. Samaik et al.
CLINICAL CANCER RESEARCH (2011)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Vijayakumar Velu et al.
NATURE (2009)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
